Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Medtech Guidance Tracker: January 2022

Executive Summary

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight documents have been posted on the tracker since its last update.

You may also be interested in...



IVDR Clinical Evidence: EU Guidance Document Spells Out What Is Required

The long-awaited guidance on how to collect and maintain clinical evidence for diagnostic tests under the IVDR has now been published. It reflects the need for a lifecycle approach to device development and regulation.

2 Become 1: FDA Takes Trip Down Combo Products Premarket Pathway In New Guidance

The 28 January guidance from the US FDA explains the premarket and submission process for combination products and offers tips to manufacturers as they consider which of the agency’s lead centers should review their product.

Roche’s Eye Drug Scores First UK Approval Under Access Consortium

The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.

Topics

UsernamePublicRestriction

Register

MT145030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel